|Bid||0.00 x 3100|
|Ask||258.56 x 1800|
|Day's Range||252.01 - 256.10|
|52 Week Range||208.07 - 287.94|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||19.16|
|Forward Dividend & Yield||4.32 (1.69%)|
|1y Target Est||N/A|
UnitedHealth, Honeywell, Wayfair, AT&T, Microsoft and Impossible Foods are the companies to watch.
The laboratory services company beat Wall Street estimates despite reporting only modest revenue growth and another earnings decline.
Envision CEO Chris Holden has been an outspoken critic of the practice which he calls “surprise coverage."
The Dow Jones Index is having an amazing year. From its January low of 22,686, the Dow Jones Index has surged nearly 5,000 points to top 27,000 for the first time. With such huge gains, it's time to start thinking about what Dow Jones stocks to sell.As you'd expect, when the market as a whole rips so much, it sets up some great profit-taking opportunities in individual stocks out of the Dow Jones' 30 components. * 7 Defense Stocks to Buy to Fortify Your Portfolio From vulnerable healthcare stocks to overpriced consumer staples plays and more, here are five Dow Jones stocks to sell before the market slides again.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stocks To Sell: Boeing (BA)It has been baffling watching Boeing (NYSE:BA) stock recently. You would have expected a massive correction in BA stock since several of the company's jets crashed, calling into question the safety of the Boeing Max line of jets.Instead, BA stock has been astoundingly resilient. This would be one thing if BA stock had already been cheap when the safety issues began. But no, BA stock wasn't cheap at all. It had just quadrupled in value since early 2016 and reached its highest P/E ratio in years in March.It seems that investors have forgotten that the airline industry is cyclical. Yes, oil prices are low right now. Airlines are making a lot of money for the moment. When airlines make huge profits, they order planes. In fact, they order too many planes. This cycle has happened every few years dating back to the 1960s. Yet investors seem to think this commercial aviation boom will go on forever. It won't.On the military side, yes, orders have been up. But analysts modeling this upturn in defense spending indefinitely will also be disappointed. What happens if and when the Republicans lose power in Washington? There's also the little matter that we have no idea how bad the issues will be from the Boeing Max situation. BA stock is still really expensive. Coca-Cola (KO)Source: Shutterstock The chase for yield has investors rushing back into a lot of slow-growing defensive companies. The rationale makes sense on the surface. Lower interest rates mean that bonds are less attractive investments.Yet investors, especially retirees, still need current income. So they sell their bonds and other fixed income holdings to buy stocks with larger yields. Coca-Cola (NYSE:KO) is one such popular stock.It's not hard to see the appeal of KO stock as a bond alternative. It yields more than U.S. Treasuries or bank CDs while offering a dividend that Coca-Cola has increased every year for decades on end.However, cracks are forming in Coca-Cola's growth and income story. Namely, there's hardly any growth.Soda sales have plunged in America and other developed markets. Emerging market growth has largely offset this so far, but there are limits to that. Soda sales may drop even more sharply going forward as more jurisdictions implement sugar taxes. As a result, Coca-Cola has hardly grown in recent years - it has taken on more debt and boosted its dividend payout ratio to keep the yield going up. That works for a while, but without organic growth, Coca-Cola's dividend stream will turn to a trickle over time. * 10 Tech Stocks That Are Still Worth Your Time (And Money) Based solely on earnings, for a slow (or at times no-) growth company like Coca-Cola, you'd rarely pay more than 20x earnings, if that. As such, it's hard to justify KO stock being worth more than $45 now. If you own KO stock solely for the dividend, it's a fine holding. But don't anticipate much, if anything, in the form of share price gains over the next year or two. McDonald's (MCD)One has to wonder if McDonald's (NYSE:MCD) is about to launch CBD-infused burgers. Or perhaps a national Beyond Meat (NASDAQ:BYND) burger rollout. That is to say, investors are bidding up MCD stock like it's a hot craze, even though its business momentum is decidedly pedestrian at best.In fact, many of the company's franchisees have been complaining. All-day breakfast greatly increased complexity for operators and raised labor costs without doing much for overall revenues. McDonald's is also asking its franchisees to make extensive store overhauls even though the local operators haven't exactly been rolling in cash flow lately. Franchisees sent a harshly-worded letter around earlier this year demanding that:"We can NOT afford the waste that a 'one size fits all' reinvestment program creates […] We must allow our owner operators to take back control of the reinvestment that is happening, stop the useless and problematic investing, and focus our reinvestment in what will actually produce a return on investment (drive thrus and kitchens)."Over on Wall Street, however, no one seems worried about McDonald's questionable strategy in recent years. MCD stock is up 36% over the past 12 months and is up more than 22% year-to-date. This has led McDonald's to sport a bloated 28x P/E ratio. Investors are likely to get indigestion when they look back at paying more than $200 a share for MCD stock. UnitedHealth Group (UNH)Source: Shutterstock If you watched the first Democratic presidential debate, you probably won't be too surprised by this pick. A sizable number of candidates, when asked if they would get rid of private for-profit health insurance, raised their hands in affirmation. The political world has moved a lot since 2016, when Bernie Sanders' suggestion of abolishing private health care seemed radical.Now, there's a decent chance that the eventual Democratic nominee will be pushing to outlaw or at least greatly curtail private insurance going forward. Would that nominee, if elected, be able to push legislation through what will likely still be a Republican Senate in 2021? Probably not.Still, do you want to own a private insurer like UnitedHealth Group (NYSE:UNH) ahead of the election? Absolutely not. Even if you think the Republicans will keep the White House, think back to 2015. * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip Hillary Clinton went on the attack against Martin Shkreli and biotech firms for jacking up prescription drug prices. Biotech stocks collapsed shortly thereafter. Private health insurers are about as popular as nuclear waste dumps with a large portion of the electorate. With the presidential election still a year away, politicians have plenty of time to threaten and demonize firms like UnitedHealth. Sell this recent pop in UNH stock; it's toxic given the political environment. Johnson & Johnson (JNJ)Source: Shutterstock On a similar note, Johnson & Johnson (NYSE:JNJ) also exposes investors to a great deal of political risk ahead of the election. JNJ is a highly diversified business with many consumer care products that are (mostly) above reproach.But JNJ also sells a lot of prescription drugs, and both Trump and the Democrats are making loud noises about going after pricing, which would cut into JNJ's margins. Trump's efforts to curtail drug prices appear to be stalled for the time being. But make no mistake, the issue is a perfect one for politicians to use to drum up votes during election season.Johnson & Johnson also has its liability issue related to baby powder products which allegedly led to cancer. It is exposed to large verdicts against it related to this. Presumably JNJ will be able to reduce its liability greatly over time as cooler heads prevail, but for now, it's another big overhang on JNJ stock. If JNJ stock were cheaper, you could discount the political worries; it's a very strong and diversified company. But at this valuation, JNJ stock could easily have more downside before it bottoms.At the time of this writing, Ian Bezek owned JNJ stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Defense Stocks to Buy to Fortify Your Portfolio * 10 High-Flying, Overvalued Stocks in Danger of Crashing * 8 Stocks to Buy That Are Growing Faster Than Amazon The post 5 Dow Jones Stocks to Sell Before the Market Slumps appeared first on InvestorPlace.
Markets closed lower on Friday after a report stated that Fed officials would reduce the benchmark interest rates in its next meeting by only a quarter percentage points.
Tom Huber has steered the fund through a lot of different markets with consistent results over the past two decades. A year after the first cut, the payers in the S&P 500 were ahead of the nonpayers by 5%, they noted.
Despite a better-than-expected earnings report, the stock did not respond to the upside given uncertainty related to the 2020 election.
The Energy and Commerce Committee in the U.S. House of Representatives advanced several health care initiatives Wednesday, the most significant of which could curb surprise medical bills.
U.S. stocks close higher Thursday, recovering from early losses, after New York Federal Reserve President John Williams said the central bank’s wisest strategy is to cut interest rates at the first sign of economic distress when interest rates are already low.
UnitedHealth beat earnings views, but said full-year revenue might miss views. UnitedHealth stock fell after flirting with a buy point before the open.
UnitedHealth Group Inc. raised its full-year profit outlook on Thursday after reporting second-quarter earnings that topped Wall Street expectations.
UnitedHealth earnings for the second quarter of 2019 have UNH stock falling, despite positive results.Source: Shutterstock UnitedHealth (NYSE:UNH) reported earnings per share of $3.60 for the second quarter of the year. This is a roughly 15% increase over the company's earnings per share of $3.14 from the same time last year. It also comes in well above Wall Street's earnings per share estimate of $3.45 for the quarter, but UNH stock is still down today.The UnitedHealth earnings report for the second quarter of 2019 also includes net income of $3.39 billion. This is better than the company's net income of $3.01 billion reported in the second quarter of 2018.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOperating income reported in the UnitedHealth earnings release for the second quarter of the year comes in at $4.74 billion. Operating income from the same period of the year prior was $4.20 billion.UnitedHealth earnings for the second quarter of 2019 has revenue coming in at $60.60 billion. That's up from the company's revenue of $56.09 billion reported in the second quarter of the previous year. This also has it beating analysts' revenue estimate of $60.59 billion for the quarter, but it couldn't stop UNH stock from falling. * 7 Stocks Top Investors Are Buying Now So why exactly is this UnitedHealth earnings report not boosting UNH stock today? It looks like it has to do with how the company beat estimates. An unexpected increase in nonoperating income contributed to it beating estimates. This doesn't have UNH shareholders stoked about the results.UNH stock was down 2% as of noon Thursday, but is up 9% year-to-date. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks Top Investors Are Buying Now * The 10 Best Cryptocurrencies to Keep on Your Radar * 7 Marijuana Penny Stocks That Could Triple (But You Won't Make Money) As of this writing, William White did not hold a position in any of the aforementioned securities.The post UnitedHealth Earnings: UNH Stock Dips Despite Q2 Beat appeared first on InvestorPlace.
Earnings season is underway and corporate buybacks are set to boost earnings per share for S&P 500 companies.
The Dow Jones Industrial Average midday Thursday was being yanked to session lows by a trio of components. Shares of UnitedHealth Group Inc. , Boeing Co. , and Walt Disney Co. were exacting a powerful 100-point drag on the blue-chip index, representing the lion's share of the modest declines in the price-weighted benchmark. The Dow was down 135 points, or 0.5%, at 27,089, while the S&P 500 index was sinking 0.3% lower at 2,975, with the Nasdaq Composite Index 0.5% lower at 8,143. A $1 move in any one of the Dow's components equates to a roughly 6.8-point swing in the index. UnitedHealth shares were down $6.75 at $259.90 a share, a decline of 2.5%, those for Boeing were off $5.83 to reach $363.57, a drop of 1.6%, while Disney's shares were edging 1.4% lower, off $2.03 at $140.52.
U.S. stock indexes edged lower on Thursday as investors awaited more developments around trade, while Netflix posted a surprise drop in U.S. subscribers, kicking off earnings for the FAANG group of stocks on a sour note. Losses in Netflix also dragged the communication services sector, one of the best-performing S&P sectors so far this year, 1.20% lower. "Netflix did nothing to soothe investor concerns around what earnings prospects are likely to unfold over the next couple of weeks," said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.